The EMA’s CHMP has endorsed Ondibta for diabetes and Osqay for osteoporosis, a move that could broaden access to effective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback